Gleiss Lutz advised private equity firm Investindustrial on the acquisition of Aakamp Group by Farmaceutici Procemsa S.p.A., a company indirectly held by Investindustrial Growth L.P.
Aakamp Group develops and produces food supplements. It has its own manufacturing facilities and currently employs around 200 people. Farmaceutici Procemsa specialises in the research and development – as well as the production, packaging and sale – of food supplements, medical devices and cosmetics for third parties.
By entering the German market through the integration of Procemsa and Aakamp, Investindustrial seeks to continue its strategy of creating a European leader in cosmetics and food supplements. The transaction is expected to be completed by mid-April 2022.
Investindustrial was advised by the following Gleiss Lutz team: Dr. Jan Balssen (lead, partner, Munich/London), Dr. Olaf Hohlefelder (Munich), Dr. Christoph Meissner (Berlin), Maximilian Imre (Stuttgart, all Private Equity), Dr. Stefan Mayer (partner), Dominik Monz (both Tax), Dr. Tim Weber (partner), Maximilian Leisenheimer (both Real Estate, all Frankfurt), Dr. Doris-Maria Schuster (partner, Hamburg), Dr. Hauke Darius Wolf (both Employment, Frankfurt), Dr. Alexander Molle (partner), Jan Felix Hinrichs (both Berlin), Dr. Matthias Werner (counsel), Dr. Theresa Uhlenhut (both Munich, all IP/IT), Frank Schlobach (partner), Dr. Jan-Alexander Lange (counsel, both Banking and Finance, Frankfurt) and Dr. Manuel Klar (Data Protection, Munich).
Gleiss Lutz has already advised Investindustrial on its previous investment in the Atida Group.
Forward
